PADDING
UNK
,
of
the
.
and
in
)
(
with
to
a
:
patients
that
for
gene
by
was
is
*
on
=
were
/
The
or
polymorphisms
as
-
polymorphism
expression
cancer
not
associated
treatment
an
response
In
be
genotype
study
1
%
P
are
receptor
;
between
alcohol
cells
mutation
cell
We
association
2
EGFR
3
we
but
may
therapy
levels
significantly
treated
activity
have
after
A
effects
+
this
inhibitor
from
clinical
which
mice
genetic
significant
-induced
risk
mutations
chemotherapy
allele
than
at
CYP3A5
dependence
<
dose
increased
effect
results
these
kinase
CONCLUSIONS
role
higher
human
compared
has
found
promoter
resistance
also
p
group
breast
protein
p53
CONCLUSION
who
among
RESULTS
genes
genotypes
n
variants
did
CYP2C19
showed
warfarin
reduced
combination
increase
To
-based
CYP2C9
studies
CYP2D6
had
subjects
tacrolimus
mutant
survival
suggest
METHODS
CYP3A4
status
C
This
efficacy
wild-type
population
sensitivity
toxicity
been
drug
metabolism
advanced
Our
single
their
HER2
plasma
lower
NSCLC
factor
lung
cocaine
mRNA
transporter
both
VKORC1
growth
carriers
chronic
concentrations
plus
administration
no
drugs
acid
nucleotide
tumors
its
SNP
well
]
use
whether
influence
activation
TPMT
model
inhibitors
other
tumor
alleles
95
SNPs
exon
[
one
serotonin
induced
These
BACKGROUND
more
HLA-B
-dependent
cytochrome
different
nicotine
against
P450
only
during
Chinese
4
first
ABCB1
including
control
differences
ratio
vivo
MTHFR
type
dopamine
variability
present
10
BRAF
two
concentration
those
development
lines
observed
related
COMT
colorectal
high
examined
show
pharmacokinetics
while
either
KRAS
indicate
all
receiving
can
functional
ribavirin
data
tamoxifen
when
major
used
line
serum
paclitaxel
clopidogrel
Japanese
benefit
blood
controls
function
platinum
CI
irinotecan
involved
deficiency
analysis
previously
tyrosine
common
women
dependent
such
findings
apoptosis
using
respectively
within
0
signaling
presence
6
investigated
oral
vitro
daily
evaluate
responses
-positive
-treated
demonstrated
healthy
decreased
into
>
reduction
haplotype
induction
OBJECTIVE
based
might
inhibition
groups
liver
demonstrate
affect
erlotinib
alone
II
investigate
metastatic
years
hypersensitivity
heroin
Patients
potential
whereas
early
acute
transplant
exposure
variant
dehydrogenase
hepatitis
low
mg
important
5-HTTLPR
Association
changes
pathway
first-line
target
greater
age
agonist
recipients
MDR1
variation
associations
could
thiopurine
therapeutic
without
novel
aspirin
renal
deletion
doses
shown
region
predictor
MTX
homozygous
5
manner
hepatic
known
'
number
following
test
ethanol
5-FU
through
combined
analyzed
identified
overall
assessed
predictive
adverse
B
synthase
disease
mean
contrast
genotyping
level
neurons
cases
melanoma
OR
epidermal
further
trial
However
clearance
inhibited
our
studied
imatinib
-related
conclusion
0.05
outcomes
DNA
T
0.001
abacavir
pharmacokinetic
expressed
carrying
-mediated
phase
AND
agents
it
reductase
determine
cancers
susceptibility
Nrf2
enzyme
I
5701
h
maintenance
standard
metabolic
CC
c-fos
interindividual
activated
-mutant
reported
useful
proliferation
5-fluorouracil
effective
increases
rat
leukemia
impact
virus
UGT1A1
coronary
estrogen
CpG
azathioprine
Using
12
Although
suggesting
aim
measured
do
8
frequency
four
IL28B
progression-free
enzymes
less
regimen
's
relationship
appears
specific
beta
followed
rate
genotyped
addiction
affected
sensitive
interaction
men
kidney
brain
No
behavioral
encoding
anti-
better
abuse
vitamin
hypothesis
screening
time
rates
detected
nitric
CYP2A6
disposition
patient
cohort
S
channel
oxide
odds
via
smoking
glucose
lansoprazole
contribute
haplotypes
normal
vs.
relation
molecular
induces
9
death
syndrome
domain
value
methylation
doxorubicin
cellular
single-nucleotide
7
subunit
review
considered
There
Phase
support
ITPA
nucleus
regulatory
binding
receptors
difference
CBZ
assess
parameters
assay
highly
revealed
DRD2
influenced
Moreover
cholesterol
populations
area
inhibiting
multiple
expressing
current
similar
arsenic
individuals
carcinoma
docetaxel
lithium
potent
system
seen
African
primary
methamphetamine
driven
cyclophosphamide
evaluated
trastuzumab
Val
reduces
ovarian
GABRA2
oxaliplatin
cetuximab
because
PIK3CA
risperidone
poor
required
affects
testing
It
play
sustained
factors
adjuvant
PURPOSE
outcome
anthracycline
ratios
C3435T
events
under
metabolizers
disorders
developed
weight
and/or
schizophrenia
addition
there
antagonist
strong
clinically
received
cisplatin
indicating
extracellular
pharmacodynamic
c-Fos
established
evidence
proteins
DPYD
determined
infection
CREB
substitution
baseline
included
prognostic
suggested
transplantation
40
adenosine
ALK
phosphorylation
C677T
SLCO1B1
if
tandem
injection
AD
virological
interactions
recently
platelet
Cancer
SVR
occurrence
tested
harboring
accumulation
regression
peginterferon
AUC
KIT
SIRT1
additional
mg/kg
enhanced
ligand
5-HTT
responsible
interval
confidence
days
least
methotrexate
individual
CYP2B6
per
body
prior
correlated
morphine
change
"
iron
analyses
Here
anxiety
non-small
mechanism
result
cyclosporine
lipid
crizotinib
relapse
CYP4F2
complex
Genetic
locally
0.03
possible
gefitinib
ABCG2
predict
some
BRCA1
BDNF
recurrence
hypothesized
induce
ADH1B
TNF-alpha
pretreatment
20
CHC
PFS
male
interferon
GSTP1
cardiac
phenotype
AR
When
disorder
DAT
part
small
persistent
elimination
metabolites
haloperidol
11
MET
provided
drinking
inhibits
Arg
asthma
.0001
severe
marker
before
ALL
opioid
caused
directed
although
N
17
-mutated
6-mercaptopurine
prostate
metabolized
lead
HFE
weeks
thymidylate
1B
knockout
i.e.
estradiol
total
Therefore
depletion
comparison
endothelial
AIMS
purpose
alpha
reactions
Fos
r
16
prevalence
sorafenib
finding
likely
0.01
active
ability
urinary
celecoxib
each
non-small-cell
responded
Polymorphisms
concentration-time
selection
damage
will
dose-dependent
glutathione
extensive
curve
several
sequencing
androgen
coding
toward
stage
gemcitabine
stable
diet
trend
respond
particularly
versus
showing
previous
reward
any
injury
however
models
improved
thus
same
VNTR
requirements
ERCC1
diabetes
28
1G
microg
enhances
vemurafenib
profile
-resistant
transcriptional
exhibited
mechanisms
selected
SJS
due
resistant
confer
lapatinib
ER
seem
encoded
Val158Met
content
HIV-1
TEN
angiotensin
depressive
direct
volunteers
One
large
COX-2
strongly
decrease
Group
case
plants
involvement
independent
nuclear
oncogene
inosine
organic
indicated
impaired
24
P-gp
75
alterations
III
alter
Breast
-specific
nor
American
myelosuppression
HLA-C
domains
heterozygotes
report
inhibit
point
Among
subset
cAMP
S-methyltransferase
radiation
hepatocellular
activities
substrate
calcium
targets
homozygotes
where
After
constitutive
muscle
dosage
fact
influences
Resistance
MCL
27
statins
agent
include
CYP2C8
CFTR
regardless
MEK1/2
adrenergic
MLL
CYP3A
clear
vs
formation
vascular
self-administration
promoted
treatments
probe
ATM
p21
abnormal
.02
hormone
lack
striatal
positive
poorer
pancreatic
history
carried
ARE
glutamate
chemotherapeutic
work
performed
suicide
ACE
PEG-IFN
provides
hydroxylation
pharmacogenetic
toxic
regions
c-myc
arrest
phenotypes
adult
insulin
Mutations
homocysteine
appear
TKIs
childhood
shows
towards
explore
non-
GSTT1
unresectable
APAP
isoform
primarily
neoadjuvant
European
CYP
Z
2A
promising
characteristics
G
day
diminished
Effect
orally
tissue
authors
pharmacological
viral
endogenous
capecitabine
determinants
JAK2
isolates
ADH2
pathways
A118G
hydroxylase
index
nelfinavir
plasmid
tissues
targeted
should
relevant
atherosclerosis
possibly
L
aggressive
three
TT
improve
Furthermore
reverse
colon
distribution
action
Caucasian
histone
lesions
triglyceride
CD4
50
rs9934438
randomized
preference
located
antigen
correlate
correlation
FLT3
place
epithelial
even
dyskinesia
Since
approach
performance
b
does
affecting
Korean
capacity
months
pattern
essential
order
year
uptake
achieve
secretion
whose
Cyclin
thrombosis
mouse
carboplatin
t
EPHX1
lipase
receive
Lung
rt
most
abnormalities
given
tumour
frequencies
release
RBV
adjusted
GSTM1
D
HO-1
metabolizing
metformin
membrane
predicting
fentanyl
AZA
rs9923231
continued
XRCC1
epoxide
degree
favorable
mesylate
examine
polymorphic
constructs
hematopoietic
prevented
DESIGN
intraperitoneal
profiles
Effects
HLA-A
member
recent
tolerance
MDR-1
pharmacodynamics
preclinical
Pharmacogenetics
rs2108622
ERK1/2
safety
15:02
variable
five
predicts
secondary
properties
negative
identifying
restored
modulate
out
behavior
month
failed
01
Maintenance
c-
lysine
XIAP
TYMS
D4
HCV
psychosis
linear
-expressing
phenotyping
Accordingly
PATIENTS
GCV
clozapine
OBJECTIVES
marked
Depression
containing
investigation
harbored
Hsp90
mitochondrial
differentiation
multidrug
fludarabine
-associated
start
IDH1
On
grade
require
protect
cADRs
GABA
nicotinic
acenocoumarol
K
D1
mg/m
TS
kinetics
decreases
elevated
61
markedly
?
/neu
HIV
experimental
Additionally
chloride
symptoms
Tamoxifen
WT
Hb
dabrafenib
-TKI
MDR
catechol-O-methyltransferase
mitotic
bevacizumab
diabetic
inositol
together
altered
15
ADRB2
oocytes
60
overexpression
partial
immediate
regulate
R-
consistent
250
duplication
immunity
RFC1
down-regulates
descent
Bcl-2
Based
refractory
administered
tryptophan
antiretroviral
enhancement
downstream
regulates
they
substrates
CDA
MMP-2
NF-kappaB
sensitization
MMA
antiapoptotic
murine
Cyp51
much
At
TNBC
selective
hippocampal
ALDH2
corresponding
larger
alcoholism
missense
twice
doublet
basis
Na(+)
CHFR
reporter
respect
memory
C/T
deaminase
distinct
sirolimus
open-label
week
so
thereby
CYP2E1
central
Results
median
sample
t.i.d.
hours
lamivudine
upstream
Thus
carry
males
Also
R
HBV
HLA-
lymphoma
OPRM1
52
-negative
tumours
smoke
hemoglobin
17-AAG
striatum
minor
US
UGT1A9
ABCC2
Tacrolimus
replaced
74
Treatment
modest
dynamics
size
OS
-binding
transfer
focused
folate
initial
malignant
nevirapine
dihydropyrimidine
carrier
sex
CYP2A5
Epidermal
rechallenge
probably
LDL
rs1057910
approved
TNF
myeloid
avoid
CYP1A1
contributed
family
0.06
dystonia
subfamily
M184V
trials
transferrin
digoxin
21
predominantly
extracted
Inhibitor
antitumor
mCRC
classes
molecules
MK
PSA
yet
subgroup
codeine
CD8
TOP2A
synthetic
nasal
Japan
PDYN
paroxetine
follow-up
transcriptase
TK
-targeted
Ras
cytotoxicity
new
-5
pilot
translocation
26
injections
0.02
certain
acetylcholine
variations
NAT2
3A4
phenylalanine
second
HR
immunization
inhibitory
infusion
bone
carbamazepine
designed
100
preoperative
negatively
triphosphate
dexamethasone
female
PR
pharmacogenetics
SLC6A4
cassette
PD
invasion
L858R
70
especially
inducing
PPARalpha
placebo
200
Sp1
withdrawal
extent
loss
plays
EGCG
For
biosynthesis
checkpoint
according
cytogenetic
reactivated
pfmdr1
Caucasians
PEG
antibody
produced
PTH
everolimus
genetically
NMDA
Is
RFS
Polymorphism
c.
stent
develop
myelogenous
pressure
gastric
antiplatelet
losartan
laboratory
Molecular
heterozygous
setting
intronic
humans
iNOS
L90M
ADV
percutaneous
150
lipoprotein
protective
mutants
identification
surface
find
25
PACAP
transcription
DRD4
EXPERIMENTAL
3101
transferase
would
up-regulated
C/D
hypermethylation
Lack
MEK
then
lowering
MDS
rs8099917
13
aimed
-overexpressing
low-dose
radiotherapy
solid
NPY
sulphonylureas
Sorafenib
Vemurafenib
GGCX
-tolerant
B1
PXR
failure
peptide
worse
DA
kinases
incidence
CCK
Met
extract
signs
Americans
six
provide
inducible
specificity
craving
pain
improves
modulates
steroid
correlates
PPI
0.26
An
dosing
rise
P50
suppression
UNASSIGNED
reaction
5-HT
skin
mediated
phosphorylated
statistically
improvement
amphetamine
voriconazole
mellitus
methylenetetrahydrofolate
understanding
efavirenz
V600E
.04
suggests
ODN
virologic
14
prospectively
upregulated
like
cycle
them
absorption
values
greatly
meta-analysis
LSZ
peak
30
norepinephrine
undergoing
molecule
K-ras
hepatotoxicity
Previous
pegylated
allopurinol
determining
antidepressant
noted
Transplant
AA
series
particular
seems
loss-of-function
MGMT
postmenopausal
noncarriers
TLR9
stress
TKI-resistant
hormonal
measures
Gefitinib
Specifically
1.1
tool
luciferase
1D
prediction
conclude
resulted
HT
already
depression
BCR/ABL
BCR-ABL
contributes
analogs
NADPH
activator
Dutch
adjacent
discounted
block
general
concurrent
zidovudine
sequence
modulator
pivotal
MDRI
Following
Erlotinib
DAPT
Intracerebroventricular
density
indicative
highest
CAR
markers
quantify
immunogenicity
SERT
estimated
older
non-SVR
transformation
aldehyde
treat
conferring
T1
DPD
bioavailable
hK2
CHRNA4
bupropion
c-Jun
0.04
vinorelbine
oxycodone
mutated
activate
ADRs
white
AERD
dystrophin
remained
sucrose
able
RY10-4
systematic
attempts
Influence
suspected
Activating
near
carvedilol
reversed
skeletal
occurring
LL
aspects
derived
propranolol
additive
C-RAF
VEGF
rs7294
spontaneous
glioma
inferred
retinoic
0.305
heart
intervention
confirm
MUT
biomarker
intrinsic
salmeterol
NE
3435C>T
progressive
q21
CES1
Inhibition
attributable
a2-subunit
0.0003
candidate
NPM1
potently
children
M1
e.g.
accompanied
2C19
high-
summary
cytidine
man
225
progression
HbA1c
RUNX1
kg
patterns
activating
field
rs776746
treatment-naive
S-warfarin
codons
immunosuppressive
SSRI
1A
Sk-Ov-3
max
dyes
5-MTHF
x
cortex
achieving
Common
intracellular
emission
Findings
insertion/deletion
SNAG
consolidation
cytosolic
DRD3
cerebral
BSC
TNFalpha
Four
-terminal
A2
once
dominant
sterol
geometric
valproate
repeated
stem
pyrophosphatase
areas
address
monotherapy
rs6265
6-BG
glial
creatinine
VDR
6-MP
72
females
TNF-a
mutation-positive
midazolam
matrix
acetyltransferase
Cr(VI)
linked
0.34
oxidase
investigating
2D6
native
None
rsGFP
demonstrating
cysteine
S-mephenytoin
accounted
polymerase
debrisoquine
whole
cutaneous
4-HNE
JAK3
specifically
child
Age
LTA
48
IFN-gamma
modifications
escalating
repeat
AF4
Bax
Polish
mediate
bortezomib
Single
explained
nephrotoxicity
ESRD
rs3213207
post-transplantation
complete
_
DHPG
EML4
DGF
describe
fraction
0.034
mg/dL
23
UGT1A
C0
ventricular
beneficial
-TKIs
basal
cytotoxic
Taxol
leading
Val66Met
0.007
techniques
being
Many
CHRNA5
H
venous
constructed
19
hepatocytes
Tat
anticoagulation
streptozotocin
demethylase
taxane
caffeine
relevance
MPA
ENO2
-containing
77
icotinib
longer
prescribed
now
lectin
successfully
option
0.5
log-transformed
invasive
anemia
DHFR
ventral
8-OHdG
VHL
abnl
TKI
strain
Beta2
Liver
Pharmacogenomics
prevention
I3C
mu
stenting
MCRC
overload
NPHS2
immunohistochemistry
schizophrenic
tea
neuropathy
express
AML1
mammary
limit
side
caspase-3
ER/
Alcohol
concluded
Similarly
TT/CC
confirmed
amplification
influencing
mu-opioid
excellent
Long-term
underwent
SD
maternal
sleep
58:01
acutely
Genomic
cytarabine
conditioning
-sensitive
approximately
transformed
C/C
Pak1
blockade
alcoholics
conversion
HLA-G
GG
Conversely
OPRK1
C282Y
resulting
fibrosis
alanine
elevation
Th2
-eGFP
c.1236C>T
X
channels
implication
aged
376
prescription
h/mL/mg
APOE
microinjection
preventing
N-methyl
RET-PTC-1
documented
accounts
cocktail
RIP3
17-OH
long-term
chloramphenicol
life
maximum
karyotype
ADH1C
headache
ADORA2A
augmented
Tyrosine
OCT2
Phe
hippocampus
information
From
rats
HSP90
MEK1
young
Stevens-Johnson
Growth
-regulated
retrospectively
immune
Recent
Drugs
second-line
efflux
indicates
hazard
heavy
VCAM-1
overexpressing
WFS1
differ
objective
eNOS
potentially
pregnane
application
neu
despite
rejection
water
dramatic
routine
NNK
677C-->T
BMD
myocardial
extinction
importance
anaplastic
cortical
98
attenuate
Indian
phenotypic
.005
exhibit
45
consumption
testosterone
sites
signal-regulated
Ins/Del
needed
C57BL/6
pigmentosum
stages
protects
rs6465084
microM
reuptake
TPN
dextromethorphan
60.7
loading
kappa
simple
08:01
absent
Neither
neurotrophic
gadoxetic
polyps
MLKL
applied
led
neurotransmitter
cyclooxygenase
antiproliferative
systemic
activates
possibility
Cmax
intestinal
6-hydroxydopamine
necessary
necrolysis
endometrial
ARM
protocol
POR
metastases
species
corr
separation
mild
published
context
hypothesize
periods
homologous
afatinib
More
c.3435C>T
dysferlin
Identification
Another
flecainide
S-transferase
subsequently
restenosis
CXCL8
frequently
1-(m-chlorophenyl)piperazine
supports
C>T
bleeding
DISCUSSION
Ser9Gly
ivermectin
frequent
challenge
(V600E
makes
adjustment
src
Ile
TPH1
diagnosis
Kinase
opening
oseltamivir
RET
adequate
neo-adjuvant
consumers
FDA
1.37
overcomes
Pcorr
cultures
rare
apparently
thyroid
acquired
replicated
tobacco
familial
phosphatidylinositol
intravenous
prostaglandin
principal
neuronal
acetaminophen
DTNBP1
consecutively
inflammation
3C
observations
recognized
accumbens
RRM1
ethnic
endocrine
eye
mTOR
affinity
Catechol-O-methyltransferase
MOH
PDGFRA
antidepressants
105
various
TP53
GO
inorganic
Han
neither
inhaled
signal
p16
GNB3
nucleoside
Multiple
Evidence
functions
orthologs
times
abolishes
Dex
salbutamol
leukaemia
myeloma
Asian
yield
smokers
LAM
increasing
consequences
down-regulation
Indians
dehydroepiandrosterone
SNPA
weekly
Cys
naloxone
taxanes
immunoreactive
scores
p.Gly143Glu
DDP
fluorouracil
MAO-A
mdr1a
A/G
0.1
E
subsequent
artery
regulation
E2
screened
onset
enhance
Carriers
p16INK4a
finger
HCC
suppressed
multikinase
fumigatus
prasugrel
interleukin
experiments
Both
epirubicin
TLR7
components
detect
consequence
supplement
Combination
folic
cessation
06:02
systolic
T>C
interacts
identify
pretreated
T315I
5-HT(3A
metoprolol
co-trimoxazole
independently
delayed
substitutions
A218C
stroke
pravastatin
-1438A/G
4.0
fibroblast
analgesic
concomitant
microsomal
Acquired
functionally
progenitor
V600K
PACT
medulla
myoclonus
Warfarin
staining
isoforms
DOR-1
Thai
hematologic
separate
c-Met
CRC
rapid
delay
comparable
fertility
rs12979860
controlled
attributed
leads
suppressor
Finnish
adherent
-deficient
atorvastatin
sequenced
NQO1
anticancer
intensity
73
repaglinide
effusions
Human
rs2884737
IMO
utility
CAT
amino-acid
azacitidine
BRCA
anaemia
collies
stratified
glucuronide
consisting
300
chromatin
INH
excretion
help
compounds
non-drug
ALDH1A1
Study
irreversible
cardiovascular
RAS
goal
MSI
Jun
ng/mL/mg
D2
neurotoxicity
Q151M
pooled
predictors
glucokinase
alcoholic
incubated
Pi
dramatically
upon
TCDD
supported
plasmids
ATP-binding
pre-treatment
Wt
AIM
Parkinson's
IFN-alpha
cognitive
prognosis
fluorescence
With
axial
c.428G>A
While
rifampicin
1502
levodopa
safe
bispectral
cFos
oxidative
equivalent
efficiency
Oral
chromosome
Rhes
Currently
CsA
characterized
Potential
all-trans
seeking
exposed
M
sulfate
1A1
regulated
MnSOD
production
trait
Singapore
-like
natural
blocking
animals
CBZ-epoxide
CYP1B1
systematically
ALT
S.
talinolol
peroxisome
BEZ235
adrenal
combining
multicenter
ErbB-2
null
hTERT
DD
A2/A2
BCL-2
GSK-3
0-infinity
Bcr-Abl
ve
MDR2
very
xeroderma
internal
0.004-0
GST
mixed
enhancer
bile
telaprevir
CD
MC
still
MM
Regulation
until
interest
RT
encodes
angiotensinogen
acts
met
Impact
tomography
therapies
introduced
consisted
cation
D-aspartate
thymidine
users
44
AZD6244
pleural
precipitated
overuse
Src
tagging
reduce
amiodarone
severity
positron
emtricitabine
portion
post-
personality
partly
CQ
P2Y12
exacerbated
2C9
/day
delta
skipping
aromatase
glucocorticoid
-141
insights
monoclonal
learning
presented
shorter
TAC
pregnancy
protection
XPD
harbouring
antagonists
irradiation
1.5
obtained
Studies
proliferator-activated
SJW
transporters
dopaminergic
African-American
critical
psychological
postoperatively
PCR
PTGS2
GH
escitalopram
types
medication
.002
beta2-adrenergic
average
sodium
5-azacytidine
propofol
MATERIAL
abolished
tenofovir
cluster
TD
pronounced
CT
sunitinib
fat
ZNF
DMA
vaccine
-selective
segments
desensitization
relative
P-glycoprotein
LFA-1
implying
evaluation
H-ras
Han-Chinese
dose-adjusted
c-jun
antisense
defects
pridopidine
correlations
Nav1.5
terms
slices
availability
having
cigarette
avoiding
catabolism
objectives
RAF
decline
Cdx4
antioxidant
NO
METH
Hcy
expressers
defining
anticoagulant
oncogenic
0.009
deficits
CYP1A2
ng
final
families
Ser49Gly
borderline
explain
34
supplementation
chosen
eIF3a
H3
slow
ANKK1
TAM
CDT
high-dose
500
-1
occur
glycogen
mutation-negative
Needle
HT-29
RAD51
-Induced
subclone
0.010
intragastric
antagonistic
predicted
5-
chemoprevention
25.1
evident
currents
mitomycin
ECOG
A.
analgesia
Acetaminophen
GSTs
-responsive
P446L
MOR-1
LIPC
region-Abelson
Female
retina
UDP-glucuronosyltransferase
(HLA)-B
intestine
aliphatic
truncated
acarbose
Australasian
co-segregate
phenobarbital
/low-fat
mitotoxic
contribution
lithospermate
Toll-like
Dose
Thirteen
targeting
HC/LF
hsCRP
-to
Aspiration
aberrant
20.0
IPA
BCR
coordination
S326C
non-intoxications
rs13273672
ERalpha
deferoxamine
CHOP
inductive
irradiated
narrow
PAHs
metastasis
5-oxime
linkage
deficit
RU-24969
late-onset
Gly16Gln27Thr164
HRAS
intoxication
doubled
PDGF-R
cost
lineage
strains
percentages
PVN
CHC-I
quality-adjusted
inconsistencies
MDA-MB-231
initiated
/SHOP
domain-containing
cohorts
C1-Like
HLA-DR
mmol/L
0.023
vasospasm
Similar
contributions
Modelling
person
dichotomized
210
16.23
Selectively
158/108
1.11
RE-challenge
age-adjusted
-activating
-30G>A
vulnerability
PON1
GACI
perception
saquinavir
cautiously
T_T
NME1
blot
assessing
0.063
CD34
Triallelic
ER-alpha
Primary
haplotype-specific
E2-induced
Functionalized
Twenty-four
generates
-mutations
huntingtin
.95
characteristic
18
Ranbp2
beta-hydroxylase
hepcidin
bladder
D30N
tolerability
withstand
newborn
Smad3
regarded
MATERIALS
min
tetrodotoxin
Mutated
EIACs
TTX
deep
copolymer
R/R
Evaluation
CDDP
C3-C6
GST-M1
88
transiently
nephrotic
mid-digital
favourable
OUTCOME
reasonable
estrone
residues
caspase-8
consumes
magnetic
Genome-based
Participants
pulmonologists
proinsulin
0.60
ERN1
Differential
mefloquine
overexpressed
0.511
condition
interference
H1-antihistamine
CES2
I50V
monomethylarsonous
HCV-1
speculated
HER-2/neu
epicutaneous
Crizotinib
Lymphoma
Celecoxib
cysteines
disulfide
CBZ-diol
.007
SK-OV-3
presents
Presence
line-derived
removed
low-density
become
IPASS
representative
-reactive
UGT1A7
202475-60-3
1.10
.The
Taiwanese
WCA
-R
ATP
Ps
339-345
obese
descending
-scanning
4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline
PPARa
theories
47.6
high-level
bath
MPH
loricrin
asked
252
cause
N265M
ABO
Drd1
MSNs
1V136
makers
SCH58500
wild-types
BO-653
wall
pertinence
Intriguingly
SU11274
mGluR
measurements
Malaysian
fluoropyrimidines
epilepsy
na
cleaved
Val34Leu
ERK1
Q56P
metastasis-free
ineffective
liposomes
incorporated
phases
CaMKII
R406
flux-based
potentiation
peripheral
playing
CPP
vaccination
hemodialysis
-38
ART
overanticoagulation
alpha4beta2
irinorecan
rs16147
DEX
limited
correction
leptin
GC
thrombotic
appearance
Trial
supraventricular
living-donor
simplex
Herpes
neutropenia
Monitoring
vector-mediated
nigra
(V617F
prevents
XIII
coagulation
cues
transforming
pCR
SFRS3
eriocalyxin
biochemical
siRNA
aflatoxin
aggregation
chromosomic
Cytochrome
IMPase
Jo2
Tenofovir
GR
c-abl
cells/animal
SNRI/
ensues
estrogens
extra
4-fold
StAR
drastically
buspirone
syndromes
CH4987655
MBL
simvastatin
Levels
confirms
feasible
Y621L
Purified
ferritin
four-drug
heat
guarantee
difficulties
delays
ritodrine
mineralocorticoid
sulfating
allozymes
debrizoquine
cytogenetics
phosphatase
86Y/Y184/1246Y
pLXRN-4SRE-fPA
pathogenic
fusion
malignancies
success
Asn680Ser
drink
Ile(462)Val
SRs
90-fold
progestin
members
600-mg
oxygenase-1
last
CL4
0.3331
NZW
accumbal
OATP
Small-molecule
mm
l
multivariate
recommended
Recipients
waking
questionnaire
PDA
limb
0.031
LOGIK1004A
Shh
hedgehog
BAG-1
embryo
placement
1.46
ST
Egyptian
covariates
pCAL-
interfering
p-value
p-values
MPAG
MT1A
A-alleles
0.430
usefulness
DAT1
G172T
HTR3A
germline
violence
1.005
co-mutation
endometrium
pmol/min/mg
RCK2
19.95
stimuli
simulations
1.101
Ser10Ser
0-12
transfusion
polyphenols
SCD
16Gln27Thr164
canine
PKAI
/injury
rs886003
utilization
mutation-induced
elucidate
single-stage
15-keto-PGE2
abusers
endotoxin-associated
chance
benefits
analogue
rs4653436
0.16
widely
/ARE
Women
ganciclovir
calretinin
TPO
transfecting
reach
extreme
415-426
initiation
protease
why
-2005
tBHQ
rs9263726
22
p.I359L
1.22-6
IVS12-5676A>G
tissue-binding
significance
rash
enters
lethally
network
SNP11646
RGS2
ablation
40-50
TGF-b1
prescribing
3.5
8-oxoGua
bilayers
GABRG1
planar
haemolytic
PEW
Lyon
codon
pills
prolongs
sulphone
Adenosine
s/s-allele
Egfr
afforded
Jordanians
1,647
VX-770
core
compound
aetiological
conduct
favor
ameliorate
ht1
non-expressors
GTPase
c-Kit
establishment
immunized
detrimental
ceramide
IgG1
Homozygosity
GSTO1
cefadroxil
rs1695
apomorphine
entities
Iressa
IgG2a
carotid
neural
46
Ile105Val
18B
nateglinide
p.R144C
IHC
hybridization
FISH
muraglitazar
transfected
/C
699G>A
rs156697
GSTA1
therapy-pretreated
39
measurable
rs2071888
CSNK1E
picryl
Ala189Val
Conditional
IVS4+76G>A
SCARB1
comprising
metabolisers
intron
B10
Situations
Analysis
neck
modifying
chronically
instrument
Lipoprotein
184
subscale
AUY922
1.11-1
3-hydroxy-3-methylglutaryl-coenzyme
dideoxynucleoside
129SvEv
rs1126647
adipose
acitretin
0.001-0
cell-based
lambda-3
FK506
drug-resistance
rs165599
HSV-
oligonucleotides
enterocyte
LoVo
SKOV-3
non-expressers
Saururus
phenotypically
opiate
Inter-individual
Comparison
alpha-hydroxylation
multicentre
generations
Hydralazine
genome-wide
contributory
N-acetyltransferase
Ala-
contained
gene-environment
confounders
shortened
co-morbidity
Bucindolol
protocols
translate
transmission
IL-1B
calcium-sensing
multi-
symptomatology
coumarin
alpha4
AIAU
except
XBP1
ring
Few
sensation
instability
6.5
FR-pQBI25
biomarkers
deoxycytidine
blocks
polyphenol
cascade
40.7
-3.04
L/L
nigrostriatal
chose
-wildtypes
15-fold
ABCB2
GALR1
substantially
rs2305948
pathological
+24
methylphenidate
NSHL
Carbohydrate
African-specific
APP/PS1
-835
thickness
zinc
c.2846A>T
Fourteen
enhancers
healthy-volunteer
regresses
NAD(P)H
paper
transcript
consented
Asp299Gly
earlier
dismutase
exon-skipping
I141M
randomised
neuropathic
retrospective
LDLT
front-line
yohimbine
3.8
albumin
limitations
relapsed
modification
SCFAs
recipient
-485C>T
subtype-specific
distinguished
modulating
Y1
folinic
-.234
222
explored
288
Tac-QD
Twenty-seven
governed
eradication
lipids
recall
testicular
drinks
Importantly
swelling
integrin
ultrarapid
cardiomyopathy
costimulatory
Ala
IU/L
Gene
TO
Lansoprazole
monitoring
-1.2
cuff
Smad2
Single-nucleotide
La/g
drinkers
6.2
nitrosamine
defence
intact
exerts
Raf
gammaH2AX
Knockout
ASMko
outpatient
-hypersensitive
distinguish
Heterozygous
Cooperative
94
264.7
Abacavir
G143E
efficient
CDK1
genetic-potentiated
research
neoadjunctively
firstly
metabolize
RARa
subjective
design
PC
5-lipoxygenase
endemic
substantia
antibodies
CIMP-positive
48h
Kainic
-deficiency
olaparib
reasons
point-mutated
paraventricular
Kyushu
2.24
fracture
(S)-3,5-dihydroxyphenylglycine
environments
too
4.33
offered
rs11085735
phosphorus
CTL
computer-assisted
Bt2
0.534
22,
creatine
All
altering
sertraline
equilibrative
TYMP
future
remission
transporting
traditional
mg/day
PC-BSA
STMN1
BRCA2
235T
mortality
RO4987655
chinensis
S-1
.023
characterize
differential
2.371
Hsp90alpha
rs1128503
0.82
rs1076562
78
-Related
Th1
anteroventral
1.5-fold
Recurrence
IM3829
autonomic
GFP
Targeting
significiantly
GRIN2A
needs
IOR/OS-1
M204V
novo
validation
performing
hypertension
AMD
/SN
7.5
upfront
rs4952
drive
monogenic
forkhead-associated
y
long-chain
EFV
complement
+14.4
CES
participants
279
T286A
Aspergillus
S65C
product
symptomatic
Discovery
allografts
V71I
differentiates
C.
816
LXR
transmittance
14.18
knockdown
CD55
Given
logistic
well-characterized
CRH
CPT
analyze
Val30Met
alteration
habits
Apoptosis-related
.74
ACHN
Inventory-II
advance
.01
lymphovascular
0425
HLSZ
microscopy
Niemann-Pick
IMs
deletions
P1655
haemoglobin
microsatellite
Pdyn
PSC
86
-1175
environmental
homozygosity
1954
barely
421
immediately
247
discontinuation
verapamil
often
FEV
abrogated
Adjusted
augmentation
Screening
ABCA1
trametinib
p450
underlying
naringenin
program
score
link
104
Several
0.94-1
curcumin
permutation
tolerable
ng/ml
RB1
6G-->T
dogma
milbemycin
lipoprotein-
1.6-fold
0.35
A1
necrosis
3.25
UDP-glucoronosyltransferase
Hsp90beta
cooperate
releasing
food
MAIN
involve
probability
counts
macrophages
-AT1
ErbB-4
addicted
appropriate
17-Hydroxysteroid
SN-38
demographic
diagnosed
mainly
aggregometry
percentage
apply
+8.6
IL18
ADP
G010401
examining
relationships
remaining
comparisons
PARP
0.005
5-HT3
M41L
0.002
myocyte
.62
Merieux
preferred
antigenicity
Sv
naturally
Sonic
sarcomatoid
EPT
12-year-old
R296C
external-beam
prevent
random-effects
spinosad
LDF
180.1
affective
alpha-globin
p25
chi2
Metoprolol
breakpoint
Detection
Whereas
PKA
SSRIs
usual
LTD
Withdrawal-induced
Toxic
well-tolerated
fetuin-A
IFNL3
IL36RN
ChD1
DPYSL2
-1.3
copper
dehydratase
respiratory
MT
Chronic
-45C>T
resection
phenacetin
unchanged
PDAC
2013
subnuclei
Kuwaiti
PMH
V118I
over-represented
ages
JTC801
meta-analytic
I/R
NH2
PEG-IFN-alpha-2a
ARRY-142866
-transferase-omega
-all
rs35597368
Veliparib
reliable
reserve
Na
-prevalent
signalling
knock-out
Combinational
Regarding
Cu/ZnSOD
rs1934951
immunocompromised
colonic
Enzyme
Cyp3a5
0.12
NZB
R408W
WNT
DMXAA
evoked
cyclosporin
8.46
matrine
RASSF1A
hMOR
DNAs
Scale
evidenced
[MMA(V)
regimens
2,000
LS
5-FC
transaminase
interferon-free
.I148M
p.Glu542Lys
bacterial
CMI
Southeast
omega1
Functional
13-diacetate
MAO-B
val66met
PD-0332991
TRb
DT-diaphorase
:10.1038
bulk
p-fluorofentanyl
AT1R
preoperatively
NRAS
nalbuphine
RDEA119
Pharmacokinetics
profoundly
Rare
TTR
Prevention
Tri-Phosphate
seizures
(CYP)
topiramate
3.517
POPular
psychiatric
parameter
Before
plasmatic
AhR
taxol
MspI
engineered
motives
hyperthermia
ITF2357
lenalidomide
effector
Kirsten
intramuscular
Month
template
Green
shRNA
determinant
Male-specific
repeats
OGG1
-initiating
ACS
Colorectal
intrathecal
Hydrochlorothiazide
9-month
monophosphate
feature
81
problems
polyphenolics
peripherally
Expression
JBCRN
helped
SCNN1A
experiences
Examining
Asp(9)Asn
WHI-P131
methiodide
curative
HEL
peroxide
transcription-3
three-locus
dorsolateral
restricted
guide
smaller
definite
contributing
Met233Ile
radioactive
They
centrally
DSF
APOC3
abstinent
PS
polycythemia
677
INTRODUCTION
haploinsufficiency
SQSTM1
definitive
.0004
G-Rg1
860
infarct
SNP23
surrogate
PDD
hippocampus-dependent
blockage
phosphatidylcholine
pretetanic
PROC
aminotransferase
7.3
individualised
vehicle-treated
1.61
convergent
synergism
process
propionate
BI-TK
assessment
relapse-free
A1166C
Huntington's
epigallocatechin-gallate
Novartis
event-free
resting
PVP
changed
Vinca
APL
boost
2.31
.0005
chain
Arg555Trp
rs4925
solvents
thienopyridines
Peg-rIFNa-2a
C-65
HER-2
15-PGDH
FKBP5
genetically-determined
candidates
0054
Compared
highlight
mL/min
Mediterranean
double-strand
confocal
non-selective
T-
elective
Overcoming
1069
MC1R
GCTATA
remains
raltitrexed
oxypurinol
demethylation
10.2
Patient
busulfan
time-related
KCl
prefrontal
backcrossings
contains
littermates
C>G
vinblastine
mg/kg/d
sensitizes
bCD
mercury
kainic
location
1173
POG1
1075A/C
MMR
personalized
up-regulating
A156V
Leukemia
157
hypoxia
contraceptive
L4-L6
CG
A1/A2
basal-like
polyneuropathy
rs671
viral-mediated
15-pS
P26R
cysteamine
analogous
+17.1
0.016
hypersomnia
empty
low-fat
saline
42.9
G15631T
CL
Kv1.5
EC
automatically
pramipexole
stomach
limits
M253T
ICER
converting
somatostatin
c.421C>A
hamsters
carnitine
b-blocker/sympatholytic
Journal
conditional
VerifyNow
PC-3
prophylactic
HLA-G010403
implicit
Gilotrif
A549
und
specification
ethnicities
DdeI
preprodynorphin
Xenopus
measuring
CD80
small-molecule
rectal
Thalidomide
Gly16Arg
surprising
Rapid
516TT
CAN
GUT-70
bilaterally
crystal
isoniazid
HepG2
minimal
focus
GENDEP
HTRA1
KCNA5
acetylation
closed
rs4680
c-kit
cervical
Cycloheximide
SN-38G
rs1059288
raclopride
CUDC-101
rs6943555
CRAd
ARE1
2006
C-MYC
range
islet
1.14-2
co-administration
472,200
demonstrates
2C
147
SNAI1
0.393
PET
Asthma
trough
-Mutant
82
Instead
HAGE
traits
Factor
TCF1
trioxide
etiology
ENPP1
leucine
pneumoniae
NK
PGR
luminal
intraindividual
G12D
N-terminal
muscimol
reliably
procarcinogens
PI(4,5)P2
enrichment
CCT5
rs3957357
-for
SNAI3
Thiopurines
gonadotropin
presentation
example
f
geographic
GIRK2
O6-benzylguanine
-evoked
Recently
remarkably
6.0
developing
unfavourable
0-6
Associated
leucocyte
AWS
CTX
dose-corrected
elevate
Abl
rs2228576
Single-Nucleotide
intolerance
Infection
flushing
myelodysplasia
Drug
carisoprodol
PCI
respiration
sweat
marrow
adenoma
p-
YAC-1
CCKBR
Itraconazole
presently
1826
HTPR
zif/268
International
mug
MVA
Env
b2-receptor
E+P
0.018
controlling
Leukaemia
First
hepatocyte
A1298C
.05
MGP
delta-aminolevulinic
TG/TC
gamma-carboxyglutamic
MAbs
Solute
HDAC6
MBC
ACTH
hypotheses
1.52
manipulation
tricyclic
endothelium
T-lymphocytes
additionally
Fgl1
inhalation
POMC
immunoreactivity
possession
okadaic
cold
carbohydrate
stimulation
isoflavone
montelukast
positively
53
catalytic
521TC
Current
DU-145
0.028
DCK
post-transplant
virtually
executive
SLC6A12
5-HTR2A
Receptor
Pharmacokinetic
420
promote
non-interferon
80
tablets
177
a-2
periventricular
polarizing
maintained
orally-active
Pharmaceuticals
proteasome
Akt
expansion
BECN1
LPS-induced
reactivation
3.73
2B6
existence
Ainu-selected
conducted
sexual
PlateletWorks
cooperative
C0/D
expressors
anastrozole
Variability
assays
networks
-acetyltransferase
triphosphatase
Wogonin
-1.4
/EBPb
G565A
E(2)
pertuzumab
prostaglandins
.57
ABL
rs35349697
co-administered
substance
moderated
above
done
almost
Ab
dl-PFC
infants
commercially-available
MDMA
-.212
PTEN
pleomorphism
crisis
Gastric
Five
.1
non-synonymous
amyloid
emilin/multimerin
GABAA
DFS
expectancy
0.003
2.91
beta1
28B
GP
0.792
0.08
Institut
dorsalraphe
Transplantation
proteinuria
Preventive
55.2
LPS
close
0.628
donor
up
exploratory
0.88
1.01
short
4-OH-TAM
hydroxyurea
Cho
antagonism
azole
situ
Taq
IGF-1
deacetylase
similarly
GIST
VKORC
Newly
0.19-1
normalized
pulmonary
.006
risks
view
B-cell
340
misfolding
.049
tapering
damages
myocytes
TIMP-2
Asn334Ser
.0002
itself
thought
ABCC1
rs622342
JANEX-1
localization
kb
SRE-1
ameliorates
practice
33
Icotinib
letrozole
mdx
mdr1
0101
.90
multi-kinase
47
enzyme-inducing
S107
stasis
Arg389
Pak
CB1-R
HSD17B5
LSZS
equally
Doses
ApaI
Associations
schizophreniform
underanticoagulation
Homer1
fluorofentanyl
MARCKS
chemokine
-Adrenergic
EGP-2
transient
-1.0
cyclin
heritable
disappearance
47-year-old
Possible
hydroxylase-immunoreactive
NFATc4
cilengitide
V617F
element
Inhibiting
enterocytes
Fms-like
airway
Normalized
Two
mono
rs9479757
BRCA-2
Available
prostatic
duodenal
m
signature
HCC-1937
medulloblastoma
dibutyryl
CRHR1
D314A
CCR3
primate
FGF2
injected
30.93
Maprotiline
HMG
Norepinephrine
vincristine
i.p.-primed
promoter-bound
malondialdehyde
anxiolytic
FINDINGS
decrement
G0103
pSTAT5
addicts
18years
robust
F227L
interferon-alpha
immunomer
gene-promoter
ADAL
likelihood
90
CF
PI3K
myelodysplastic
227.8
parasites
c
importantly
IUI
RyR2
Proguanil
Analysing
Asn(453)Ser
CRT
FcyRIIIa
expiratory
antimode
numerous
3A
NRXN3
French
immunodeficiency
0.45
gastroesophageal
alkylating
colitis
PU.1
S/S
Pompe
duplications
doxifluridine
CYP450
controversial
threshold
1.34-150
saturation
v-raf
androstenedione
4-week
laboratories
N86/184F/D1246
knock-down
entire
NRTIs
-exposed
Within
hydrolase
beyond
micromol/L
xenobiotics
manifestations
hand
intracerebroventricular
Fifty-two
TH
A2A
-hydroxylase
POLG
instead
BH4
Consequently
DR5
ligand-independent
Herceptin
infarction
NAT1
non-R/R
distant
nonresponders
Substituting
IIA
transglutaminase
reinvestigated
Native
C3435Tpolymorphism
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
parkinsonian
/AML
grey
HN31
hydrochloride
polyphenolic
autochthonous
HRQoL
E-3174
hemachromatosis
rs3745274
loop
SULT1A3
requirement
promyelocytic
key
MPTP
NVP
Major
positivity
Parkinson
Most
Adenoma
alpha-hydroxymetoprolol
neurotoxin
Poly(ADP-ribose)
GISTs
selectively
fourfold
co-occurring
TRAG-3
dimethylarsinic
G1
P1635
comparative
-16
L2/L3
CiVDR/PXRa
EC50
ipsilaterally
DM1
BPRS
0.033
surgery
nM
AZD1152-HQPA
pectenotoxin-2
7.2
rs307826
subacute
6477-6763
Haloperidol
AMH
left
0.50
1000
ERK
medium
pPVN
MZ
nonischemic
peg-interferon
Arg389Gly-
-adrenergic
(HCV)
MN
rGH
forced
triheptanoin
N236T
hyperplasia
Implementation
CPIC
guidelines
bound
Clinical
MOCOS
L180M
alkaloids
leucovorin
toxicology
Scientific
-LPR
F1
ALOX5
Salmeterol
declined
CB
terrestrial
glucosinolate
c-erbB-2
Variation
TaqIB
short-chain
biopsies
plant
FRA
biosynthetic
phenylpropanoid
regulator
interfered
Capparales
metabolite
0.49
.00003
fluoropyrimidine
RIalpha
TAS2R16
Maxdrinks
brain-derived
CCl(4)
Val(660)Leu
nonsmall
light
Taq1
1236C>T
vector
identifies
considerably
individualization
rs7089580
ACC
-abuse
innately
worsen
hearing
Gsta2
proteoliposomes
Mannose
aminoglycoside
C303
Sult2a1
C6
intertwined
great
newly
BSS
mAb
751Lys
Multitest
Neuroscience
NOS2
atypical
54
Dopamine
antigens
GZD824
40-250
/Met
requiring
phorbol
event-related
0.264
neuroprotective
mesoderm
responds
chorea
Body
hyperacetylation
fluvastatin
Network
R184S
8.48
.69
-terminally
cosegregates
attenuated
online
enantioselective
Omacetaxine
pantoprazole
weak
Compound
mmol/l
high-density
accuracy
HRT1B
hypothyroid
donors
rs4795893
gamma-aminobutyric
PDGFR
largely
composed
Cyclin-dependent
MK-801
-37C-->A
usage
22.5
CDK9
HSC-2
set
3H1
INR
Taq1A
II-
rs2619539
1.27
I/D
synaptic
culture
P1635-
NJ
G>A
CHD
conventional
-1639
insight
hydrolytic
omeprazole
infertility
rhesus
monkeys
IVF
MMC
-116C/G
displays
equal
factor-alpha
sought
P-TEFb
predilection
inter-patient
how
Mitochondrial
inducers
blasts
generally
symptom
Ph
14.17
SAQUINAVIR
0.20
Selumetinib
shunting
ortholog
susceptible
CONCLUSIONS/SIGNIFICANCE
endpoints
RR
favored
deficient
probucol
-inducible
0.75
EGC
PNA
discovery
antibiotics
PDLIM5
probable
sudden
PNA-AAV6,
PNA-AAV8
PC12
CNR1
17-(beta-D-glucuronide
Intercellular
rs4646437
Exposure
IRENE
mGlu3
ryanodine
variance
3.64
FSHR
levamisole
Arg194Trp
spent
victims
23.6
comparing
about
313
immunoprecipitation
arms
insertion
RTV
nearly
non-carriers
column
interfere
cirrhotic
relations
rIFNa-2b
butyrate
isolated
That
CoCl2
toxicities
0.54
regulators
0.11
CPT-11
0.15
delivery
immunoassays
Latex
g.-1639G-->A
ASMF
rs1870377
flow
dysfunction
-stimulated
Dabrafenib
ectopic
investigates
enrolled
Individual
site
deaminase-like
GS-9219
diflunisal
IL-10
ACh
interactive
HTR3B
individually
booster
impair
fisetin
KEY
arachidonate
pallidal
vegetable
0.622
FCGR3A
TaqIA
Y
lymphocyte
rabbit
AVT
converging
fluticasone
gastrointestinal
cytosine
diffuse
true
RGS3
CRF
thermolabile
ABCC4
Drd2
.22
0.017
47His
c.2677G>T
47/376
every
FTND
Hepatoprotective
TCA
animal
2016
argues
pharmacogenomics
[C-X-C
ALDH1b1
time-dependent
triggered
NSCLCs
CYP19
Nyholt
37/61
5q
1.31-4
S9
Imiquimod
protruded
1F
r-ATG
123
periaqueductal
His95Arg
decisions
CYP3a13
emerged
olanzapine
mimics
T369I
adenocarcinoma
1.75
mimicked
Ad5-
miR-122
Stromelysin-1
Diagnostic
causes
Pro12Ala
UGT2B7
secondly
PepT1
procured
C825T
rs9332127
TaqI
apoE4
rs11076161
beta-fibrinogen
T69N
Ester
overview
cis-platinum
Hepatic
oridonin
flu
synergistic
.49
Cholesteryl
SCF
taste
HGF
encephalopathy
give
resistance-associated
CHEK2
molecule-1
sharply
RT-PCR
access
DFMO
MOR
TAG
MS
breakdown
radiosensitization
2.2
7-days
pegylated-interferon
3.83
TDBPs
0.95
CNI-
methylated
amprenavir
KCNQ1
beta(4)
anthracyclines
sessions
benefiting
follicles
XPA
MiaPaca2
sulphonylurea
magnitude
1.7-43
IBD
FPG
therapeutics
6-month
embryonic
SiHa
antialcoholism
hypomethylation
adjust
F508del
ciclosporin
height
effluxed
-71
antithymocyte
modulated
angiogenesis
modifier
solution
oxides
carcinogenesis
arterial
Gly
Glutathione
rhodamine
nutlin-3
infant
SOD
Relative
p-fluoro
therefore
-LI
consumed
FIP1L1
Sequence
-0.54
double
A/A
neuroendocrine
125I
.2
PegIFN
MUC1
generate
NMR
partially
Collies
achieved
By
Fine
exons
Cu
disulfiram
TULIP
triple-negative
-7
beta3
haplotype-dependent
Ig
ICAM-1
intermediate
remodeling
Del
322-325
Western
Ins
lacking
tachyarrhythmia
FAK
nonfunctional
centromedial
12.5
airways
shell
recombination
94C>A
Alleles
element-1
uterus
ELK1
F617L
-agonists
Serotonin
reabsorption
Identifies
CYP7A1
corrected
real-world
cryptotanshinone
rs4149013
Immunohistochemical
.5
HoxB4
soyabean
RESISTANCE
valuable
indicators
Inventory
Slo2.2
western
tegaserod
L/S
quetiapine
codon23
C1236T
http://clinicalTrials.gov/
TAPBP
mitosis
sulfhydryl
hENT1
tranylcypromine
stimulation-resistant
yang
ALT1
conjugated
p.Glu545Lys
yeast
C77G
nonsignificant
SLCO1B3
neocortical
July
5.00
-399A
Caspase-3
adhesion
rs737865
mitogen-activated
DSG
fewer
laevis
amygdala
175
anti-HBe
IFNa-2
elderly
-Microglobulinuria
0017
maculopapular
MnCl(2)
-1639G/A
profound
1.05
VEGF-A
hyperabsorption
low-activity
clonidine
STZ
.03
71
antioxidative
cyclophosphamid
hence
remarkable
isogenic
generalize
K562
Analogously
p.Asp260fs
vera
routes
0.709
Inhibitors
define
quantitative
-3435CC
hemizygous
AOX1
bipolar
3-week
catalysis
aldosterone
Du145
beta1-AR
36
Jews
transport
retinoid
predispose
GATA4
His611Arg
G0105N
5'-hydroxy
HLA
Capecitabine
Thr260Arg
Bupropion
PML
prednisolone
giving
MFG-E8
NPY1R
SM360320
250G/A
0.054
caspase3
T1974C
elevates
pindolol
PCT
extends
AZD1152
FKBP4
3.07-65
WM
N/S
minutes
course
pharmacoepigenetic
12.57
Nebivolol
Differences
sinthase
tpj
thrombocytopenia
translated
statin
abrogates
phosphodiesterase
5-aza-2'-deoxycytidine
Preliminary
desensitizes
worldwide
brushing
sarcoma
naltrexone
macrocytosis
-514
islands
disadvantaged
well-being
Viruses
non-hematologic
spliced
0.314
5-fluorouracil-5-FUDR
simultaneously
diol
elicit
rs9606186
CA
muscular
1494C>
GABABR1
homeostasis
141
(IL)-28B
excitingly
glomerulosclerosis
IL8
replication
208
371.9
witnessed
Protective
metabolically
social
MBP
facilitated
mg/kg/h
responsiveness
Younger
lopinavir
TDL
H63D
bud
lineages
occasional
PCOS
correlating
CXCR4
3-11-fold
K562/A02
23S
highlights
3-kinase-dependent
idarubicin
head
untreated
Ecstasy
TRAIL
codes
-H
putative
degrades
unaffected
mutagenic
Trastuzumab
intake
PRIMA-1
NOS2A
-haplodeficient
Program
324
alelle
1.0-7
relatively
determination
0.93-1
observation
variabilities
prevailing
absolute
hypoxanthine
fexofenadine
bcr1
COX2
Thr449Ile
41
silencing
ERCC5
Scr
66
SNAI2
inv
facets
stavudine
dose-response
rearranged
IPPase
post
U0126
extrusion
T790M
5FU
AKR-501
woman
transducer
organization
ng/mL
emphasizing
5-(arenethynyl)
killed
Random
L.
power
-455G/A
11C
5-HT4
CYP2A8
GABRE
Ser358
differentiating
VRX-480773
revolutionized
sufficient
corticotropin
kinase-9
source
viremia
post-PCI
NCT00352014
Simultaneously
-infected
Withdrawal
agonists
Paraffin
arcuate
potency
sex-linked
rs2740574
venlafaxine
chronopharmacokinetics
MAOA
2.53
suxamethonium
+25
progesterone
CML
Need
North
mt-
56
/T
10.4
rs5376
considerations
Canadian
GSTpi
Insulin
NVALT
down-regulated
CFH
+14.3
recurrences
2011
selumetinib
biopsy
LDH
Luciferase
multi-drug
synonymous
D123G
slightly
discussed
involving
besides
NNRTI
BAFs
morphological
rs1570360
seven
allele-restricted
A1/A1
rs29230
(-)-epigallocatechin-3-gallate
implicated
Irreversible
UGT
GABAB
16HBE14o
Periareolar
FokI
rs1051266
mitochondria
aurora
FOLFOX
Phenotypic
T102C
opposing
Nexavar
radiosensitizer
participates
pombe
LTP
heterogeneity
AC
intensive
engraftment
tolerated
responding
1.89
97
concentration-dependent
F2
nonphosphorylated
fibroblasts
methoxsalen
deposits
96
liver-specific
silibinin
renin-angiotensin
Mozambique
degeneration
identical
-controlled
nonlinear
100-240
3-fold
lumefantrine
clearly
NAA
Childhood
0024
reverses
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
endoxifen
SYK
YKT6
Altogether
stress-induced
43
hypoglycaemic
F624
behaviors
prostratin
SDS
C-G
29
HCH
m-CPP
Taxotere
C-sweat
bearing
SkM1
norclozapine
prothrombotic
vasodilation
phosphorylcholine
11q
spindle
Inhibits
SLC19A1
Bag-1
sibutramine
Seven
Conjugation
GSTO2
Hippel-Lindau
G/A
manganese
hypersensitive
hair
humanized
fear
comorbidities
apoptotic
anticonvulsants
lymphoblastic
59
ranging
CYP83A1
TGF-beta
units
cycles
unique
Taking
ADIPOQ
circulation
Pooled
downregulation
rs12714145
alpha-thalassaemic
0.508
Modulation
cooperates
Histone
green
effectively
GST-P1
Oncology
rs1042714
beta2-AR
analog
INRs
encode
apnoea
prodynorphin
rs17862325
2.95
nano-imaging
promotes
abrogators
F617
antiepileptic
homologue
MAF
GAD67-GFP-expressing
produces
warrants
medial
EMs
amodiaquine
0.369
decisive
face
521TT
CETP
inter-individual
-1.6
haplotypic
nanoparticles
A-241G
starting
Tac
87.5
rs121912777
inactivation
C-to-T
IkappaBalpha
oxidation
single-arm
T939C
Gly389Gly
counterparts
Therapeutic
1.4
holds
Transforming
rs2619538
R1881
N-methyl-D-aspartate
Proenkephalin
MCJ
enrolment
11.4
placental
kinase-internal
raltegravir
H4
disequilibrium
CD86
RATIONALE
Logistic
Roscovitine
182
ABCC10
nominally
quinapril
evolution
LNCaP
-linked
copolymers
00
UGT2B15
stiffness
381.6
/5-Fu
rs1360780
prednisone
dopa
Genotyping
e
0.603
capability
PTC
MIA2
mizoribine
SNPSpD
Consortium
histological
fatalities
Y181I
42
anti-inflammatory
motor
radiosensitize
direction
Cr
glycosylated
HPLC
0.084
Thal
adenoviral
1173T/C
RAW
Arg399Gln
PASMC
concentration/dose
RAS-
ribonucleotide
ecstasy
discrete
N-oleoylethanolamine
(+)
BC
Selective
Brazilian
TDF
H3K4me2
Posaconazole
Y621
GSH
ATRA
consequently
Finally
aspergillosis
worthwhile
superoxide
GDNF
biotherapy
FDA-approved
impulsivity
Statin
bicalutamide
codon751
flutamide
Higher
polyphosphate-1-phosphatase
predisposition
lobe
NAc
Interactions
Rh
URE
biotransformation
apolipoprotein
rs689466
SS
Total
FMR1
Ezetimibe
unfavorable
indices
abundance
free
SE
co-injection
pyrophosphate
routinely
G2/M
CASE
Immediate
Donors
AZD7762
14.1
glucose-6-phosphate
immunomodulation
786-O
zygotes
dysregulation
BICD1
two-fold
commenced
measure
good
68
HTR1B
pazopanib
problematic
L-AP3
Nigrostriatal
epitope
G80A
regulating
pediatric
Saos-2
potentiates
LDL-lowering
gender-matched
70-140
/A
167
V600
modestly
rs2010963
2.9
methylene
cross-resistance
7alpha-hydroxylase
Preclinical
10.8
NODAT
structural
galanin
CEA
repair
Rats
diplotypes
0.217
Kidney
rs1800871
Concentrations
Prediction
currently
BalI
genotypic
France
adolescents
considerable
prostaglandin-endoperoxide
von
114-fold
segmental
focal
Tibetan
T0901317
tale
KCNJ11
AGT
roles
polluted
Yin
positive/
diallyl
mitogen
nine
cycling
stimulator
1C
comprehensive
NTS
rs2231142
A181V/T
-3.31
FOLFIRI
lymphocytes
liability
diazoxon
GCK
conjugates
intraseptal
sulfinic
fluorescent
1.4-fold
BCRP
AZD9291
8-week
period
-IFN
actively
transports
diverse
gene-expressed
SLC22A2
BRCA-1
structurally
-orotate
abated
Non-Small
Positive
rs1024611
weight-adjusted
rs4586
V
mol/l
/8
Syndrome
INTERVENTIONS
rs2857657
CCL2
inside
throughout
poisoned
distributed
regard
unconjugated
interleukin-3
quinazoline
arrays
IFN-a
TM5
His
CK
high-activity
triiodothyronine
G48V
international
consistently
GT
females-despite
best
follicular
derivatives
Negative
-20
BM
Gln504Lys
Gly16Glu27Thr164
delimit
.0006
FLG
16.6
7q
12p
CpG-DNA
po
ear
17p
-18
L-AP4
brazilin
Cholestyramine
5.9-19
Beck
CoA
offset
J129
LPV
Bk2r
B-Cd
spatial
PSEN1dE985Dbo
triazolam
SCAR
regressions
APPswe
within-gene
987
Arg-->Gln
ChU1
840-mg
intermittent
9-benzyl-8-hydroxy-2-(2-methoxyethoxy)adenine
fasting
Brain
question
eliminate
UTR
recorded
ISG/
suppressing
ethinyl
Pregnancy
captopril
sitosterolemia
Ala-->Val
HSFs
ROS1
I/II
T674I
slight
neurobiological
0.006
fell
0.0004-0
rely
provocation
4-aminopyridine
APC
volume
s
supersensitivity
N-desethylaminodiaquine
MAPK
acquisition
Bryostatin-1
catalyzes
80G>A
antioxidants
metabolites-had
AQ
reflecting
catabolic
optimal
7.19
SBP
illustrate
ip
fluid
Bisacurone
IL-28B
human-2
black
GLUT2
late-stage
end
BAX
rs448012
percent
mixture
adiponectin
Sensitization
proglucagon
magnesium
competence
intercalated
163.6
replacement
mechanistic
budesonide
ADH
capsaicin
311
3A5
FCER2
acquire
rs1799809
impressive
acting
Management
Efficacy
248
stratification
helpful
1alpha,25-dihydroxyvitamin
analogues
knockouts
monocytes
melanomas
HSV-TK/
rs2032582
superior
Arg389Gly
57:01
17beta-estradiol
copy
N-acetyl
hetero-monocyclic
PLDIM5
gatekeeper
0.494
D3
atenolol
.24
polypeptide
Upfront
1B1
rs13273442
anion
pERK1/2
.35
-PDGFRalpha
Models
psychotic
mutagenicity
thioguanine
(-)-epigallocatechin
OATP1B3
5-HT3AB
synergistically
clotrimazole
cholinesterase
post-operative
module
rate-limiting
publication
PAH
Cumulatively
B-RAF
rs699664
NR1I1
421CC
0.836
25-OH
crucial
suitable
CCA
dasatinib
undertreated
5,10-methylene-tetrahydrofolate
N-cadherin
acetaldehyde
b-catenin
rather
survivin
5-fluorocytosine
wildtype
platelets
Multivariate
1.08-2
inherited
-embedded
Cyclosporine
glioblastoma
bAt
establish
optimise
ILD
35
AML
glycosylase
catecholamine
hOGG1
GCKR
BMI
Further
Cocaine
c.444
MEK1(E203K
resonance
toxin
excision
check
down
6-38
subepithelial
titers
single-centre
multiple-dose
childhood-onset
ibudilast
Because
anaplerotic
Experimental
unlikely
Oxa
wt
(S)-mephenytoin
2E1
Amazonian
living
VEGFR3
rs307821
-intolerant
structure
VEGFR2
0.3
Ile160Thr
rs699947
NGFI-B
rs1260326
subtypes
atypia
rs1799853
defined
Bruton's
KIF3A
shed
cost-effectiveness
nervous
PD98059
833
cigarettes
quaternary
sulfamoyl
ligand-binding
high-risk
.2016.51
Hanover
enrollment
GP2
OEA
valspodar
alpha2C-AR
sumatriptan
HSS
exanthema
synthesis
RTQ
aims
CN-AML
ETO
FQI-induced
SR
reflect
Ratio
purine
HapC
knocking
sputum
repression
0.0007
2.64-fold
partner
projected
Ectopic
.40
SRNS
single-agent
S-methyl
Of
up-regulation
mediates
Rat
SN-38-glucuronide
unnecessary
I399C>T
Interestingly
gene-1
OSCC
5-HT(2C
reinstating
rituximab
MEASURES
Ca2+
C3
TCPOBOP
circulatory
terbutaline
CYP3A7
3T3
describes
3.182
DBH
disrupted
caudate/nucleus
flashes
hot
temsirolimus
dystrophy
S-27609
181T
TKI-na
tanshinone
Reinfecting
dimethyl
keratinocyte
c.2677G>T/A
topography
PP(i)
testis
complexed
thyroxine
rs2115819
supersensitive
FOS
JUN
explanation
KROX-24
few
PNPLA3
CEL
rs1042713
indinavir
GIRK1
concentration/weight-adjusted
adding
mostly
Development
scans
name
far
-158
Q61
circulating
hyperhomocysteinemia
Sulfotransferase
hydroxyapatite
AZD4619
heme
socio-economically
muscarinic
b-adrenergic
nortriptyline
0.025
XDH
cobimetinib
base
BEAS-2B
generation
biguanides
glucosidase
newer
PDGFR-a
I399
CR
transcripts
osmotic
BCL2L12
posaconazole
exact
reducing
thiazolidinediones
gallstone
hyperglycemia
episode
hepatotoxic
crystallography
specificities
doi
domain-like
interventions
pro-drug
fragment
PANSS
-2
sulphamethazine
5-aminosalicylate
Temsirolimus
0.19
SULT1A1
Ch17CEP
CLL
MPE
4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one
YM-64227
subtype
physiological
Vimentin
MRP1
TCA-b
HTR2A
N40D
excluding
valerenic
thromboembolic
AC0010
xenograft
autopsy
C-type
Wy-14643
charantia
desipramine
60-mmol/L
EA
--
foundation
/drug
oriental
bitter
1.16
genetics
Confirmation
Momordica
addictive
gourd
crozotinib
experimentation
Genomewide
pylori
Evodiamine
CTx
taking
Afatinib
H.
arsenate
WY14,643
causing
peroxidation
inferior
SGCE
TNF-b
MM6
-mimicking
1.47-3
clarithromycin
A2143G
NPC1L1
anti-angiogenesis
Ibruitinib
form
NFkB
lenalidamide
rRNA
GNAO1
BTK
pSTAT3
rs1045642
translocations
approval
third
withdrawn
779A/C
sleep-waking
granted
matter
Cell
Brca2
modulation
competitive
globulin
schizoaffective
et
adolescent
Prognostic
Sastre
1996
May
al.
structures
rs7687423
paradoxical
alfa
Adenovirus-mediated
W
prolonged
Particularly
cats
ABCC8
slow-wave
soon
SWS
-118
L-DOPA
glycosylation
TLR4
typing
38
forensic
advances
PEI
4'-hydroxylation
HCN1
glia
promotor
1p/19q
87
cost-effective
Angptl3
CDCA
120
pre-selected
SSG
in-depth
discuss
II/III
temozolomide
Transfer
postoperative
retain
q22
leukemias
nongenotoxic
DTH
consolidated
thalidomide
planned
hydrogen
mediator
launched
multilineage
MDM2
-tranferases
latter
Folate
a-glucosidase
experiment
FAS
Her-2
Turkish
ALAD
As
reinstatement
Homocysteine
1.39
-QD
*347_*348insA
Despite
commissural
xanthine
SAHA
motif]
phosphoribosyltransferase
Thiopurine
graft
STAT
actions
rs11676382
1.25
rs2630578
4-hydroxy-tamoxifen
Bcl-X(L)
Phenytoin
2.0
catalase
blotting
growing
rs1799884
ex
localized
-1557
hematological
1.27-2
type-1
EMID2
PTCA
South
ARMS2
2677G>T
1976C>T
0.049
T181A
HL
UGT1A6
DSS-induced
rs1799978
irrespective
ESR1
tetracycline
RECIST
intima-media
resequenced
CD40L
corticosteroids
switch
confirmation
synaptotagmin-1
xanthone
entacapone
CC-IMT
restrict
Nutlin-3
APOA5
estrone-3-sulfate
Gln27Glu
mineral
Protein
theaflavin
treating
locomotor
MT1-MMP
deficiencies
gamma
-765G>C
CyclinB1
episodes
PMF
kinetic
circadian
MMP
VPA
+7.2
mEH
200-mg
adenomas
+13.8
removal
AM251
GnRH
400-mg
1,3-butadiene
relapses
biological
silymarin
polygraphically
radicicol
unnoticed
mephenytoin
conclusions
detoxification
Rac1
0.07
brachytherapy
KU19-20
mCREB
-0.31
temperature
mg/kg/day
0.0001
HU
1-month
homology-modeled
BCSS
Combining
temperament
HH
suppressive
supra-brainstem
ChS1
Research
4a-
calcineurin
del322-325
mothers
incentive
PK
poisoning
lifetime
degradation
subgroups
NIH3T3
Onartuzumab
Crohn's
optimized
namely
Elucidation
3.6
Russian
AMP
3.55
gain-of-function
variables
methadone
recruitment
Gly389Arg
IL-1alpha
driver
MCP-1
follow
undergone
AIDS
Immunoglobulin
technological
over
personalizing
Overexpression
adenocarcinomas
converts
Val125Ile
4b-hydroxycholesterol
/RARa
delivered
CAS
cell-specific
g.15582C>T
autocrine/paracrine
modified
UGT1A8
quinpirole
Neuropeptide
butyric
alosetron
0.041
comorbid
dose-normalized
Ton.B210
workers
histocompatibility
AF9
reversible
lycopene
FBAT
XRE
simply
detail
ChF1
A107N
HMGCR
Cln
generated
17-allylamino-demethoxygeldanamycin
inducibly
substitute
enantiomer
A121N
keratin
lipoteichoic
secretory
0001
de
urine
Diplotypes
VH1
STAT3
rtA
Dukes
impairment
3TC
self-reported
apart
mithramycin
2/14
218
Roles
Trabectedin
abortion
HLA-DQ
exacerbate
MATE1
Successful
H-2
PHSF
Low
albeit
care
oxygenation
Type
surgical
antiestrogenic
20q
red
1.7
glucosinolates
389Gly
P-450
CCl4
001
many
Determination
-ARE-
Pharmacogenetic
eukaryotic
focusing
phosphate
sappan
phagocytosis
HPMA
strongest
ABCG5
3'-azido-3'-deoxythymidine
stimulated
D-serine
adriamycin
platinums
4.7
oPRL
across
discovered
profiled
Q172H
ARRY-142886
521
/S/A
NAD+
Fe
coenzyme
chick
35-kDa
w10
piece
According
orlistat
multinational
C2
mg/kg/2
exemestane
Mutational
AKT
electrogenetherapy
pathology
2/3
Microsomal
2.8
nNOS
-possibly
Considering
5.2
faster
amifostine
rs2228093
stenosis
angiography
A116N
anthropometrics
multifactorial
.6
DIO2
AGXT
serves
E-cadherin
self-infusion
stresses
dependence-related
monitored
Asians
plasticity
gingival
sirtinol
(V600
ALDH-2/2
GAA
regarding
T-T-T-T-G
1,25-(OH)2D
NR2B
lovastatin
-2.73
Animal
12,
bioactivated
management
Codeine
cooperatively
.001
nephrogenous
TLR
p-aminobenzoic
-4
18q
AZ
moderate
fall
dose-dependently
semiquantitative
1-34
SrCl2
c.521
etoposide
samples
polymerase-1
Y414C
2-fold
immunostaining
poor-risk
0.368
judged
5843-6276
understand
p50
Nicotine
features
-amplified
component
ras
breaks
WT1
IL-18
another
-9
retinol
CRBP
D2-like
A-607C
unilateral
blast
2'-O-galloylhyperin
binds
postulated
artificial
elicited
ease
spermatozoa
AIA
Arg389Arg
